ArticleFrontiers in endocrinology2026
Cardiac and aerobic response to growth hormone therapy in children with short stature: a prospective study using VO
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Recombinant human growth hormone (r-hGH) enhances somatic growth and body composition, yet its short-term effects on aerobic capacity and myocardial function remain unclear in short-statured children. Objective: To assess changes in aerobic performance and cardiac morphology/function in prepubertal children with short stature undergoing r-hGH therapy, using conventional and speckle tracking echocardiography (STE). Material and methods: This prospective longitudinal study included 30 prepubertal children (18 with GH deficiency [GHD], 12 non-GHD including 6 small for gestational age [SGA] and 6 idiopathic short stature [ISS]). Participants received r-hGH for 12 months. Assessments at baseline, 6, and 12 months included anthropometry, VO Results: r-hGH significantly increased IGF-1 and left ventricular mass indices. VO Conclusions: While r-hGH therapy led to favorable cardiac remodeling and early subclinical improvements in myocardial contractility in GHD children, no enhancement in aerobic capacity was observed over one year. STE proved valuable for detecting early cardiac adaptations to GH therapy. Further studies with longer follow-up and larger cohorts are warranted to clarify the functional implications of these structural changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.